

Elias J Sayour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4937604/publications.pdf>

Version: 2024-02-01

20
papers

724
citations

623734

14
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

1278
citing authors

#	ARTICLE	IF	CITATIONS
1	Contemporary RNA Therapeutics for Glioblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 8-12.	3.4	10
2	CAR T Cell Locomotion in Solid Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1974.	4.1	15
3	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). <i>Neoplasia</i> , 2022, 31, 100813.	5.3	14
4	Nanoparticles as immunomodulators and translational agents in brain tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 29-39.	2.9	6
5	GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction. <i>Translational Oncology</i> , 2021, 14, 100971.	3.7	19
6	Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. <i>Veterinary Immunology and Immunopathology</i> , 2021, 232, 110169.	1.2	17
7	Emerging trends in immunotherapy for pediatric sarcomas. <i>Journal of Hematology and Oncology</i> , 2019, 12, 78.	17.0	59
8	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. <i>ACS Nano</i> , 2019, 13, 13884-13898.	14.6	66
9	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2890.	4.1	44
10	Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy. <i>Nano Letters</i> , 2018, 18, 6195-6206.	9.1	58
11	Translational nanoparticle engineering for cancer vaccines. <i>Oncolimmunology</i> , 2017, 6, e1290036.	4.6	35
12	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. <i>Oncolimmunology</i> , 2017, 6, e1256527.	4.6	59
13	Immunotherapy for Pediatric Brain Tumors. <i>Brain Sciences</i> , 2017, 7, 137.	2.3	24
14	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	2.2	31
15	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 205-211.	4.2	6
16	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 582-595.	7.0	88
17	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>Oncolimmunology</i> , 2015, 4, e994374.	4.6	41
18	Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. , 2015, 3, 13.		13

#	ARTICLE	IF	CITATIONS
19	Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide. <i>Cancer Immunology Research</i> , 2015, 3, 320-325.	3.4	20
20	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e94281.	2.5	99